Formulary Search
Search Results : Parkinson's disease (Trihexyphenidyl hydrochloride - Parkinson's disease)
Records returned : 30 (on 29 May 2025 at 13:22:42).
Return to search results for ' Parkinson's disease '.
Show Icon and Status Keys
Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Capsules
- Oral solution
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Rapid eye movement disorder. Can be prescribed upon recommendation from a specialist
Links :
Indication :
Status :
Formulations :
- Capsules
- Capsules (slow release)
- Dispersible tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
- Tablets (slow release)
Restrictions / Comments:
Important
Can be prescribed upon recommendation from a specialist
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Intestinal gel
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Preferred
Preferred COMT inhibitor
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Intestinal gel
Restrictions / Comments:
Important
This product has not been assessed for inclusion on the formulary. Contact your pharmacy team for advice on making an applicationto the APC.
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Modified release tablets
Restrictions / Comments:
Important
Preferred
Rapid eye movement sleep behaviour disorder. (RBD)
On specialist recommendation
Melatonin 2mg MR tablets are the recommended preferred 1st line product
Prescribe generically. Circadin is NON-FORMULARY
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Immediate release tablets
Restrictions / Comments:
Important
Rapid eye movement sleep behaviour disorder. (RBD)
If immediate onset of action is required or crushed to aid swallowing
On specialist recommendation
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Oral solution
Restrictions / Comments:
Important
Rapid eye movement sleep behaviour disorder. (RBD)
Reserved ONLY if feeding tube in situ, or significant swallowing difficulties, and the use of the whole or crushed tablets are unsuitable
On specialist recommendation
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Capsules
Restrictions / Comments:
Important
Rapid eye movement sleep behaviour disorder. (RBD)
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Capsules
Restrictions / Comments:
Important
2nd line COMT inhibitor.
Entacapone is the locally agreed 1st-line choice
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Modified release tablets
Restrictions / Comments:
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Modified release tablets
Restrictions / Comments:
Links :
Indication :
Status :
Formulations :
- Patches
Restrictions / Comments:
Important
Consider patches if levodopa and / or oral dopamine are not effective in treating nocturnal akinesia
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Pre-filled syringe
- Subcutaneous infusion
- Subcutaneous injection (sc)
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Not a 1st-line treatment option.
On-going toxicity monitoring required
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Not a 1st-line treatment option.
On-going toxicity monitoring required
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Intravenous infusion
Restrictions / Comments:
Important
Will need tertiary centre approval before Blueteq/funding released
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Tablets
Restrictions / Comments:
Important
Not a 1st-line treatment option.
On-going toxicity monitoring required
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :
Indication :
Status :
Formulations :
- Not Specified
Restrictions / Comments:
Formulary Status :
Links :